Juvenile Xanthogranuloma: Clinical Trials

2 trials for Juvenile Xanthogranuloma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Active not recruiting 1, Recruiting 1

Follow Juvenile Xanthogranuloma: new trials by email Literature Review of Juvenile Xanthogranuloma trials Research Report on Juvenile Xanthogranuloma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Cobimetinib - Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma
Phase 2RecruitingCarl Allen902021-04-192026-10-26
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2Active not recruitingNational Cancer Institute (NCI)13772017-07-312026-07-24

Narrower conditions

Histiocytic Sarcoma (2)  ·  Histiocytosis, Langerhans-Cell (2)  ·  Xanthogranuloma, Juvenile (2)  ·  Central Nervous System Neoplasms (1)  ·  Ependymoma (1)  ·  Erdheim-Chester Disease (1)  ·  Glioma (1)  ·  Hepatoblastoma (1)  ·  Histiocytic Disorders, Malignant (1)  ·  Histiocytosis, Sinus (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Medulloblastoma (1)  ·  Neuroblastoma (1)  ·  Neuroectodermal Tumors, Primitive, Peripheral (1)  ·  Osteosarcoma (1)

Broader conditions

Hemic and Lymphatic Diseases (2)  ·  Histiocytosis (2)  ·  Histiocytosis, Non-Langerhans-Cell (2)  ·  Lung Diseases (2)  ·  Lung Diseases, Interstitial (2)  ·  Lymphatic Diseases (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Respiratory Tract Diseases (2)  ·  Skin Diseases (2)  ·  Skin and Connective Tissue Diseases (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genetic Diseases, Inborn (1)

Interventions

Biopsy (1)  ·  LY3023414 (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Nuclear Medicine Department, Hospital (1)  ·  Phantoms, Imaging (1)  ·  Specimen Handling (1)  ·  Vemurafenib (1)  ·  X-Rays (1)  ·  cobimetinib (1)  ·  ensartinib (1)  ·  erdafitinib (1)  ·  ivosidenib (1)  ·  larotrectinib (1)  ·  olaparib (1)  ·  palbociclib (1)

Sponsors

Carl Allen (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (2)  ·  Australia (1)  ·  Canada (1)  ·  Puerto Rico (1)

Top investigators

Carl E Allen, MD, PhD (1)  ·  Donald W Parsons (1)

Results publications

PMID 33591402, PMID 35353553, PMID 41166674, PMID 42686334

NIH funding

U10CA180886 (1)